Cronos launches SOURZ by Spinach® Fully Blasted Multipacks

3 months ago

SOURZ by Spinach® Fully Blasted Multipacks SOURZ by Spinach® Fully Blasted Multipacks available now. TORONTO, Oct. 09, 2025 (GLOBE NEWSWIRE)…

NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21

3 months ago

LANGHORNE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of…

CDT Equity Inc. Announces Reverse Stock Split

3 months ago

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the…

Series A Round Valuation: ¥9 Billion: MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors

3 months ago

TOKYO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter…

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

3 months ago

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical…

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

3 months ago

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will…

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

3 months ago

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics…

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

3 months ago

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the…

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

3 months ago

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company…